November 16, 2016 - By Linda Rogers · 0 Comments
Cardiome Pharma Corp (NASDAQ:CRME) institutional sentiment increased to 1.56 in Q2 2016. Its up 0.93, from 0.63 in 2016Q1. The ratio is better, as 14 funds started new or increased equity positions, while 9 decreased and sold their equity positions in Cardiome Pharma Corp. The funds in our partner’s database reported: 12.02 million shares, down from 12.67 million shares in 2016Q1. Also, the number of funds holding Cardiome Pharma Corp in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 5 Increased: 8 New Position: 6.
Cardiome Pharma Corp. is a specialty pharmaceutical company. The company has a market cap of $91.71 million. The Firm is engaged in the development and commercialization of cardiovascular therapies for heart disease. It currently has negative earnings. The Company’s divisions are Europe and Rest of World.
It is down 38.17% since April 14, 2016 and is downtrending. It has underperformed by 42.85% the S&P500.
According to Zacks Investment Research, “Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), and a pre-clinical program directed at improving cardiovascular function.”
Alphaone Investment Services Llc holds 1.1% of its portfolio in CARDIOME PHARMA CORP for 580,365 shares. Turner Investments L.P. owns 400,000 shares or 0.64% of their US portfolio. Moreover, Clough Capital Partners L P has 0.56% invested in the company for 2.06 million shares. The Maryland-based Rock Springs Capital Management Lp has invested 0.45% in the stock. Westfield Capital Management Co Lp, a Massachusetts-based fund reported 3.91 million shares.#img1#
Ratings analysis reveals 75% of Cardiome Pharma Corp’s analysts are positive. Out of 4 Wall Street analysts rating Cardiome Pharma Corp, 3 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $3.50 while the high is $12.50. The stock’s average target of $8.88 is 206.21% above today’s ($2.9) share price. CRME was included in 7 notes of analysts from August 11, 2015. The firm has “Hold” rating by Zacks given on Wednesday, August 26. The company was upgraded on Friday, May 6 by Mackie. LB Securities reinitiated CARDIOME PHARMA CORP (NASDAQ:CRME) on Friday, August 14 with “Buy” rating. The rating was maintained by Brean Capital with “Buy” on Friday, March 11. The rating was downgraded by Zacks on Tuesday, August 11 to “Buy”. The stock of CARDIOME PHARMA CORP (NASDAQ:CRME) has “Hold” rating given on Wednesday, October 12 by Mackie. H.C. Wainwright initiated CARDIOME PHARMA CORP (NASDAQ:CRME) on Wednesday, June 1 with “Buy” rating.
Cardiome Pharma Corp. (Cardiome), incorporated on March 1, 2009, is a specialty pharmaceutical company. The Firm is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s divisions are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.
More news for CARDIOME PHARMA CORP (NASDAQ:CRME) were recently published by: Marketwatch.com, which released: “Cardiome Pharma Corp.” on December 21, 2009. Quotes.Wsj.com‘s article titled: “News Cardiome Pharma Corp.CRME” and published on February 12, 2011 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Linda Rogers